Ruxoprubart (NM8074) is an inhibitor of complement factor B ( Bb subunit ). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy [1] [2] [3].
In Vivo, In healthy subject tests, Ruxoprubart exhibits favorable safety and tolerability at all tested doses[2].
References:
[1]. Peixoto VP, et al. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials. Curr Med Res Opin. Published online May 16, 2024.
[2]. Kavanagh D, et al. Factor B as a therapeutic target for the treatment of complement-mediated diseases. Front Immunol. 2025;16:1537974. Published 2025 Feb 14.
[3]. Gentile M, et al. Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review. J Clin Med. 2025;14(3):702. Published 2025 Jan 22.
In Vivo, In healthy subject tests, Ruxoprubart exhibits favorable safety and tolerability at all tested doses[2].
References:
[1]. Peixoto VP, et al. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials. Curr Med Res Opin. Published online May 16, 2024.
[2]. Kavanagh D, et al. Factor B as a therapeutic target for the treatment of complement-mediated diseases. Front Immunol. 2025;16:1537974. Published 2025 Feb 14.
[3]. Gentile M, et al. Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review. J Clin Med. 2025;14(3):702. Published 2025 Jan 22.